

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 November 2023 (16.11.2023)



(10) International Publication Number
WO 2023/220597 A1

(51) International Patent Classification:

C07K 14/55 (2006.01) C07K 14/715 (2006.01)
A61K 38/00 (2006.01)

(21) International Application Number:

PCT/US2023/066784

(22) International Filing Date:

09 May 2023 (09.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/340,294 10 May 2022 (10.05.2022) US
63/391,243 21 July 2022 (21.07.2022) US

(71) Applicant: **ELPIS BIOPHARMACEUTICALS**
[US/US]; 128 Spring Street, Building B, Lexington, Massachusetts 02421 (US).

(72) Inventors: **ZHAO, Kehao**; c/o Elpis Biopharmaceuticals, 128 Spring Street, Building B, Lexington, Massachusetts 02421 (US). **CHEN, Yan**; c/o Elpis Biopharmaceuticals, 128 Spring Street, Building B, Lexington, Massachusetts 02421 (US). **HASSAN, Samuel, Clement**; c/o Elpis Biopharmaceuticals, 128 Spring Street, Building B, Lexington, Massachusetts 02421 (US). **JIANG, Ning**; c/o Elpis Bio-

pharmaceuticals, 128 Spring Street, Building B, Lexington, Massachusetts 02421 (US). **O'CALLAGHAN, Katie**; c/o Elpis Biopharmaceuticals, 128 Spring Street, Building B, Lexington, Massachusetts 02421 (US).

(74) Agent: **O'BRIEN, Daniel** et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: ENGINEERED INTERLEUKIN-2 RECEPTOR BETA REDUCED-BINDING AGONIST




FIG. 2A




FIG. 2B

(57) Abstract: Provided herein are engineered IL2 polypeptides IL2Rβ reduced-binding agonists and fusion proteins thereof. Also provided are methods of modulating an immune response by administering an engineered IL2 polypeptide reduced-binding agonist or a fusion protein thereof.

WO 2023/220597 A1

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*